INSIGHTS ON DRUG DEVELOPMENT

• Keeping The Momentum In Pandemic Preparedness

  Learn about the partnership between the Prairie HUB and Cytiva to create RNA vaccines to target potential pandemic viruses with the aim of redefining global pandemic preparedness.

• Identification Of GLP-1 Analog Oligomeric States Using SEC-MALS

  Discover how SEC-MALS enables precise characterization of GLP-1a therapeutics to ensure formulation integrity and enhance safety, efficacy, and regulatory confidence.

• Quantification Of Semaglutide With A Reliable Analytical Method

  Explore a validated LC-MS/MS method for precise Semaglutide quantification in plasma, which features enhanced sensitivity, peak definition, and reproducibility using innovative technologies.

• Generate CHO-K1 GFP-Expressing Cells For Cell Line Development Workflow

  Discover a high-efficiency workflow for generating GFP-expressing CHO-K1 clones using automated single-cell dispensing to achieve 93% isolation success and stable expression in under five weeks.

• Support For Your Production Challenges

  7/15/2024

  Ensure your manufacturing operations run smoothly and efficiently by collaborating with experts to tackle production, processing, or quality control issues.

• Doubling Up For Speed In Biomanufacturing

  12/12/2025

  Accelerate drug development and reduce risk with parallel operations. Learn how leveraging CDMO partnerships while building internal capabilities can cut costs and speed your path to market.

• Formulation Development Of Enterically Protected Spray Dried Dispersions

  11/17/2025

  Adrulipase spray-dried dispersions were evaluated to create an orally delivered, enteric-protected enzyme. The lead formulation provided the best acid protection, rapid release, and stability.

• The Role Of Peptones In Boosting Quality And Yield

  11/4/2024

  Peptones can significantly boost CHO cell bioprocessing. We analyze their impact on diverse CHO cell lines using real-world data to assess their effects on titer, protein quality, and cell growth.

• Advanced Therapies Going Mainstream: Are We There Yet?

  11/14/2025

  Advanced therapies are nearing mainstream adoption, with cell, mRNA, and oligonucleotide treatments expanding into broader indications. Learn what’s driving this shift and what manufacturers must do.